Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: The aim of this work was to evaluate the prognostic impact of statin therapy in symptomatic patients without obstructive CAD.
Background: Information on the prognostic impact of post-coronary computed tomographic angiography (CTA) statin use in patients with no or nonobstructive coronary artery disease (CAD) is sparse.
Methods: Patients undergoing CTA with suspected CAD in western Denmark from 2008 to 2017 with <50% coronary stenoses were identified. Information on post-CTA use of statin therapy and cardiovascular events were obtained from national registries.
Results: The study included 33,552 patients, median aged 56 years, 58% female, with no (n = 19,669) or nonobstructive (n = 13,883) CAD and a median follow-up of 3.5 years. The absolute risk of the combined end point of myocardial infarction (MI) or all-cause mortality was directly associated with the CAD burden with an event rate/1,000 patient-years of 4.13 (95% CI: 3.69-4.61) in no, 7.74 (95% CI: 6.88-8.71) in mild (coronary artery calcium score [CACS] 0-99), 13.72 (95% CI: 11.61-16.23) in moderate (CACS 100-399), and 32.47 (95% CI: 26.25-40.16) in severe (CACS ≥400) nonobstructive CAD. Statin therapy was associated with a multivariable adjusted HR for MI and death of 0.52 (95% CI: 0.36-0.75) in no, 0.44 (95% CI: 0.32-0.62) in mild, 0.51 (95% CI: 0.34-0.75) in moderate, and 0.52 (95% CI: 0.32-0.86) in severe nonobstructive CAD. The estimated numbers needed to treat to prevent the primary end point were 92 (95% CI: 61-182) in no, 36 (95% CI: 26-58) in mild, 24 (95% CI: 15-61) in moderate, and 13 (95% CI: 7-86) in severe nonobstructive CAD. Residual confounding may persist, but not to an extent explaining all of the observed risk reduction associated with statin treatment.
Conclusions: The risk of MI and all-cause mortality in patients without obstructive CAD is directly associated with the CAD burden. Statin therapy is associated with a reduction of MI and all-cause death across the spectrum of CAD, however, the absolute benefit of treatment is directionally proportional with the CAD burden.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jcmg.2021.05.022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mediastinal Teratoma With Somatic-Type Adenocarcinoma: An Enigmatic Discovery by Fine Needle Aspiration Cytology.
Cytopathology
September 2025
Department of Cardiothoracic and Vascular Surgery, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India.
Mediastinal masses often present acutely as medical emergencies, necessitating prompt and accurate diagnosis. Imaging-guided fine needle aspiration cytology (FNAC) plays a pivotal role in rapidly identifying rare mediastinal tumours and differentiating them from other potential aetiologies, enabling timely intervention. Primary mediastinal germ cell tumours (PMGCTs) constitute approximately 15% of adult mediastinal neoplasms.
View Article and Find Full Text PDFPlant-Derived Exosome-Like Nanovesicles: A Novel Strategy for Targeted Oral Therapy in Ulcerative Colitis.
Int J Nanomedicine
September 2025
The First Hospital of Hunan University of Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.
Ulcerative colitis (UC) is a chronic inflammatory bowel disease, the incidence of which continues to rise globally, and existing therapeutic options are limited by low drug bioavailability and systemic side effects. In this study, we systematically investigated the challenges of the special gastrointestinal environment of UC patients for oral drug delivery, such as extreme pH, degradation by digestive enzymes, metabolism of intestinal flora and obstruction of the intestinal mucosal barrier, and summarized the potential of plant-derived Exosome-like Nanovesicles (PELNs) as a novel delivery system. PELNs are produced by plant cells and mainly consist of proteins, RNA, lipids and plant active molecules.
View Article and Find Full Text PDFPrognostic Value of Biomarkers in Chronic Obstructive Pulmonary Disease: A Comprehensive Review.
Int J Chron Obstruct Pulmon Dis
September 2025
The First Clinical Medical College of Lanzhou University, Lanzhou, People's Republic of China.
Chronic Obstructive Pulmonary Disease (COPD) is a prevalent chronic respiratory disorder characterized by airway inflammation and irreversible airflow limitation. Its marked heterogeneity and complexity pose significant challenges to traditional clinical assessments in terms of prognostic prediction and personalized management. In recent years, the exploration of biomarkers has opened new avenues for the precise evaluation of COPD, particularly through multi-biomarker prediction models and integrative multimodal data strategies, which have substantially improved the accuracy and reliability of prognostic assessments.
View Article and Find Full Text PDFThe utility of spirometry and single breath gas transfer measurements to identify low total lung capacity.
ERJ Open Res
September 2025
Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Background: Measurement of total lung capacity (TLC) requires large and expensive equipment. We aimed to investigate whether spirometric restriction and low alveolar volume measured by single breath gas transfer ( ) can be used to identify those with a low TLC.
Methods: We retrospectively analysed data from adults referred to Cambridge University Hospitals between January 2016 and December 2023.
Predictors of mortality and hospitalised exacerbations in obstructive airway diseases.
ERJ Open Res
September 2025
Department of Bioanalysis, Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
Background: In Belgium, age-standardised hospital admission and mortality rates for asthma and COPD are higher than the European average. Understanding the factors that lead to a hospitalised exacerbation and/or mortality is needed to optimise patient management.
Methods: Patients ≥18 years old obtaining two claims for drugs for obstructive airway diseases (ATC code R03) in 1 year between 2017 and 2022 were identified in Belgian nationwide claims-based data.